Oops! This is member-only content.
Please login, sign up for a full membership, or sign up for a free 30-day trial membership to access this content.
CMS National Coverage Determination: Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Transmittal # R12649CP Issue Date 2024-05-23 Subject National Coverage Determination (NCD) 200.3 – Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (AD) Implementation Date 2024-06-24 CR #13598 Provider Education MLN Matters Article...